The Role of Drug Disposition Kinetics on Cellular Transport of the Antineoplastic Agent VM-26
Author:
- 1 January 1978
- journal article
- research article
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 8 (1) , 119-135
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cellsBiochemistry, 1976
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesEuropean Journal of Cancer (1965), 1975
- Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.Journal of Cell Biology, 1975
- PTG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- Experience with 4′-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosisEuropean Journal of Cancer (1965), 1974
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973
- Inhibition of NADH-linked respiration with the anti-cancer agent 4′-demethyl-epipodophyllotoxin thenylidene glucoside (VM-26)European Journal of Cancer (1965), 1972
- 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of actionEuropean Journal of Cancer (1965), 1970